Enrolling by Invitation
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05735483
- Conditions
- Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +10 more
- Locations
-
- Clinical Research Center of Alabama Birmingham, Alabama, United States
- Phoenix Children's Hospital Phoenix, Arizona, United States
- Arkansas Research Trials North Little Rock, Arkansas, United States
- First OC Dermatology Fountain Valley, California, United States